Prognostic Profile of Dupuytren's Disease: a Cohort Study (PRODUCT)

Starting soon · Not applicable

Conditions studied: Dupuytren's Disease

In brief

Dupuytren's disease is characterized by retractile fibrosis of the superficial palmar aponeurosis, which can lead to irreversible flexion contractures of the fingers and lasting functional impairment. Widespread throughout the world, it has a particularly high prevalence in northern European countries. This has been estimated at between 3.5% and 11% in England and Denmark. This prevalence is expected to increase over time due to the aging population. Risk factors for the disease include age, male sex, heredity, diabetes, smoking, and alcohol consumption. The resulting disability is not spontaneously reversible. It affects various aspects of daily life, most notably personal care, nutrition, and social interaction. Treatment for Dupuytren's disease, whether medical or surgical, remains symptomatic to date and does not preclude the possibility of recurrence. In France, it is based on percutaneous needle aponeurotomy and surgical aponeurectomy. Its objectives are to reduce the flexion contracture of the fingers and the functional disability caused by the disease. Enzymatic aponeurosis with collagenase is also possible, but it is less well tolerated than percutaneous needle aponeurotomy. It is more expensive and not covered by health insurance. The widespread adoption of a medical-surgical strategy that positions percutaneous needle aponeurotomy as the first-line treatment could improve the acceptability of Dupuytren's disease treatment and significantly reduce its cost to healthcare systems. However, the impact of this strategy depends on the extent to which second-line surgery is required. This use has been little studied. The proportion of patients requiring surgical treatment after percutaneous needle aponeurotomy is estimated to be 10 to 18%. These data are based on small sample sizes observed over varying follow-up periods. They need to be verified in large populations using a prospective study. Moreover, the factors associated with the need for surgery after percutaneous needle ablation for Dupuytren's disease are currently poorly understood. Understanding these factors would be beneficial for optimizing medical and surgical management. It could allow for better tailoring of treatment options to the patient's individual profile.

Key facts

Study ID: NCT07353060
Run by: GCS Ramsay Santé pour l'Enseignement et la Recherche
People needed: 305
Starts: 2026-02-04
Expected to finish: 2031-02-04
Last updated by the study team: 2026-01-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Patient, male or female, over 18 years of age
Patient with Dupuytren's disease confirmed by clinical examination: nodule or cord arising from the superficial palmar aponeurosis, visible or palpable
Aponeurotic cord causing an MCP or PIP joint flexion contracture of at least 20°
Indication for percutaneous needle ablation (flexion contracture of at least 20°, functionally impaired according to the patient)
Acceptance of percutaneous needle ablation by the patient
Patient affiliated with or covered by a social security scheme
Patient having been informed and having signed a free and informed written consent
Negative urine pregnancy test for women of childbearing age

You may not qualify if…

Minor patient,
Patient with another condition, infection, or wound of the hand,
Patient participating in another clinical trial,
Protected patient: adult under guardianship, curatorship, or other legal protection, deprived of liberty by judicial or administrative decision,
Person unable to express their consent,
Pregnant, breastfeeding, or parturient woman

Where it is running

Hôpital Lariboisière — Paris, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.